UK Parliamentarians Call For A New, Internationally Competitive Pricing System
Executive Summary
Much-needed investment could be lost if the “uncompetitive” sales rebate rate is not reduced as part of talks on a new UK drug pricing scheme, some parliamentarians are warning.
You may also be interested in...
Investment In Medicines Manufacturing Must Be UK Priority
New report on UK medicines manufacturing advises the government to improve voluntary scheme on medicine pricing to drive growth.
Lords Call For UK Government To Secure A ‘Growth’ Pricing Deal With Pharma
The House of Lords held a debate on the UK’s statutory drug pricing scheme as a way of drawing attention to the need for a voluntary price deal that can revive the international competitiveness of the life science industry.
Industry Calls For Reform of England’s Unused Innovative Medicines Fund
The pharmaceutical industry says financial uncertainties are a key reason why the English Innovative Medicines Fund (IMF) – offering the potential for time-limited funding for promising non-cancer treatments where benefits are uncertain at launch - has still not been used a year after it was put in place. Industry wants the National Health Service to share the financial risk of taking part in the fund.